Proceedings from the First International Conference eBook.pdf
(
6133 KB
)
Pobierz
FOREWORD
Use, abuse and dependence on a variety of licit and illicit substances is the major public health
problem facing the U.S. and many other countries. It is the leading cause of new HIV infections,
a major cause of cancer deaths as well as automobile and boat accidents, the largest contributor
to our burgeoning prison population, the largest cause of crime, violence, domestic and child
abuse and community destruction. In the U.S. there are over 50 million nicotine addicts, at least
15 million alcoholics and problem drinkers, over 3 million dependent upon marijuana, 2 – 3
million cocaine addicts and over a million addicted to heroin. The number of “hardcore” addicts
to illicit drugs is well over 6 million. It is not surprising, given these numbers and social costs,
that theories abound as to ways to improve the situation. From total prohibition to total
legalization and numerous steps in between, arguments rage as to the best approach. For
experienced observers of the situation, not blinded by partisan beliefs and rhetoric, it appears
clear that there is no one answer.
Mencken’s observation about simple solutions “there is always a well-known solution to every
human problem – neat, plausible, and wrong” is as true now as in 1920 when he made it. Pure
“supply reduction” models founder on the rocks of “need” and “greed” – the desire for the
euphoric effects of these agents and the willingness of individuals to take risks to provide them
because of the large profits. Likewise, the pure “demand reduction” model shows it’s
inadequacy by the lack of interest of many addicts in stopping and the failures of our current
prevention and treatment programs to sufficiently either prevent or treat. We need both a
balanced model and better prevention and treatment methods.
The current view of addiction is a marriage of brain and behavior. Sophisticated imaging
procedures and basic science research into the neurobiology of reward have identified key
elements in the reinforcing effects of various psychoactive substances. Motivational circuits
underlie the desirability of abused drugs. Brain changes after prolonged use help keep the habit
going, as well as increase the likelihood of relapse after hard-won abstinence. In one sense the
reward circuitry has been “hijacked” by the rapid intense effects of chemicals at the expense of
the more usual rewarding behaviors. Successful treatment thus often requires both medications
to help cope with the brain changes and urges, as well as relapse prevention techniques and
learning to again get rewards from non-chemical means. The failure of many treatment attempts
is a testimony to the difficulty of the task.
Because of this difficulty there is a constant search for new methods – better, faster, easier. The
search for a “quick fix” is not limited to addicts – researchers, treatment providers, family
members, friends and policy makers share it at times as well. The fact that it hasn’t yet been
found doesn’t mean it can’t be found so efforts continue. The story of ibogaine for addiction is
part of that search.
One hundred years ago, as well as recently, treatment of withdrawal was often seen as
synonymous with treatment of addiction. Numerous drugs and techniques – some innocuous,
some lethal, most in between – were tried to improve withdrawal. None were successful for the
larger task of healing addiction, although some have worked reasonably well in treating
withdrawal. We still can not successfully treat a substantial number of addicted individuals. The
difficulty may lie both in the persistence of brain changes and the difficulty of making life-style
changes. The search has been hampered by the intensive warfare between those who believe any
medication is a “crutch” and those who view addiction as a medical disorder that may ultimately
yield to a combination of medications and behavioral techniques as employed in other chronic
medical conditions. It has also been hampered by the lack of interest of major pharmaceutical
firms in devoting resources to the search. Stigma connected to addiction, and a perceived lack of
possible profitability in a medication have contributed to this unwillingness. Medications could
have a variety of roles some more likely to be found than others: providing a rapid, safe effective
withdrawal; decreasing craving; providing a “window of opportunity” for the individual to
develop relapse prevention skills and alternative reinforcers; reversing brain changes; blocking
or ameliorating the effects of the abused substances; providing a cost effective way of reaching
larger numbers of individuals.
The diffusion of psychedelic drugs into the larger culture in the 1960’s led to a variety of
different uses. While some used them for “recreational” purposes, escapism, and altered sensory
experiences, others used them in religious activities, serious exploration of altered states, and at
times, formal therapy. LSD, for example was used in treatment of alcoholism. While initially it
appeared to yield promising results, manifested by a high percentage of abstinence, follow-up
studies demonstrated no sustained efficacy and efforts were mainly dropped. The rise of street
use of the drug among the young may have contributed in part to the loss of interest among
researchers but lack of efficacy appears to have been a major factor. In contrast, use of peyote to
treat alcoholism in some Native American groups has persisted for decades, perhaps because of
it’s restriction to clear religious ceremonial occasions.
Ibogaine appears to have followed in the same path therapeutically as LSD but did not become a
street drug, probably because of some quite unpleasant side-effects. Initially it was touted as
both a rapid effective withdrawal method and a cure for heroin and cocaine addiction. Later, as
relapses became apparent, it was labeled as an “addiction interrupter”, and still later as useful
mainly for a small group of “motivated” individuals. Unlike LSD, it’s use for therapy was
pushed by a variety of groups with very different agendas – as described succinctly in the chapter
by Alper et al. Since, as noted earlier, commercial interest in addiction treatment medications
was minimal, pressure by these disparate groups was aimed at government agencies – especially
NIDA and FDA, and individuals, including this author, who were mistakenly, or more likely
deliberately for reasons such as their position on other issues of interest to certain groups, were
targeted for coercive actions. Whether the actions against NIDA were ultimately helpful,
harmful, or insignificant in getting the desired results is not totally clear. My own view is there
may have been a short term gain but a long term loss because of perceived marginalization of the
drug.
More important for the long term goal of developing new medications for addiction was the
persistence of scholarly research on ibogaine in both animals and humans. Such research laid
out possible mechanisms of action and found metabolites that may be of more interest than the
parent compound. Ultimately the usefulness, or lack thereof, of ibogaine and related compounds
in the treatment of addiction will rise or fall on such research. If the drug does have useful
effects, it may be possible to develop synthetic agents that produce desired actions on addiction
without undesirable effects. In any event, Alper is to be congratulated for both the enormous
effort to put together the scientific conference on which this book is based and the book itself
which can bring the findings to a larger audience then was present at the meeting. The need for
new medications to treat addiction is as great as ever. Whether or not ibogaine is useful or not is
a scientific question that can be answered neither by street demonstrations nor by avoiding
careful controlled research. As scientists our obligation is to keep looking for safe effective
methods to prevent and treat this great international scourge.
Plik z chomika:
renzo.matryca
Inne pliki z tego folderu:
LIVROS EM PDF-20230502T163006Z-001.zip
(140356 KB)
Charles C. Ankeney - The Breath Of Life.pdf
(199713 KB)
Allan Wallace - The 200 MPG Carburetor - A Technical Expose of the World's Auto Makers.pdf
(58569 KB)
Adam McLean - A Collection of Alchemical and Hermetic Emblems - Sequences 4.pdf
(19982 KB)
Albert E. Kahn - High Treason - The Plot Against The People.pdf
(26061 KB)
Inne foldery tego chomika:
Pliki dostępne do 01.06.2025
!NOWE!
▶️ ₳ɍïēƖ Ṽāɳēāɳ
۞ Tematyka Gay ۞
AMG BRASIL
Zgłoś jeśli
naruszono regulamin